Tilray Brands (TLRY) Income from Non-Controlling Interests (2020 - 2026)
Tilray Brands' (TLRY) quarterly Income from Non-Controlling Interests came in at $12.3 million in Q2 2026, up 150.94% YoY from $4.9 million in Q2 2025, and up 689.72% on a QoQ basis from $1.6 million in Q1 2026.
Tilray Brands (TLRY) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 7 years of Income from Non-Controlling Interests data on file, last reported at $12.3 million in Q2 2026.
- Quarterly Income from Non-Controlling Interests rose 150.94% year-over-year to $12.3 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $17.6 million (up 281.51% YoY) and the FY2026 annual result came in at $17.6 million, up 227.31% from the prior year.
- Income from Non-Controlling Interests grew to $12.3 million in Q2 2026, from $1.6 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $20.3 million in Q2 2022 to a low of -$24.8 million in Q1 2023.
- A 5-year average of $4.6 million and a median of $5.0 million in 2024 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests jumped 402.74% — and 2023, when it sank 366.6%.
- Tracing TLRY's Income from Non-Controlling Interests over 5 years: stood at $7.8 million in 2022, then slumped by 63.8% to $2.8 million in 2023, then tumbled by 128.9% to -$819000.0 in 2024, then surged by 337.97% to $1.9 million in 2025, then surged by 530.89% to $12.3 million in 2026.
- The last three Income from Non-Controlling Interests figures came in at $12.3 million (Q2 2026), $1.6 million (Q1 2026), and $1.9 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Tilray Brands | 523.93 Mn | 289.30 Mn | 90.52 Mn | 12.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 12.30 Mn |
| Feb 28, 2026 | 1.56 Mn |
| Nov 30, 2025 | 1.95 Mn |
| Aug 31, 2025 | 1.84 Mn |
| May 31, 2025 | 4.90 Mn |
| Feb 28, 2025 | -4.51 Mn |
| Nov 30, 2024 | -819,000.00 |
| Aug 31, 2024 | 5.05 Mn |
| May 31, 2024 | 16.09 Mn |
| Feb 29, 2024 | -12.28 Mn |
| Nov 30, 2023 | 2.83 Mn |
| Aug 31, 2023 | 15.82 Mn |
| May 31, 2023 | 17.52 Mn |
| Feb 28, 2023 | -24.75 Mn |
| Nov 30, 2022 | 7.83 Mn |
| Aug 31, 2022 | 7.69 Mn |
| May 31, 2022 | 20.34 Mn |
| Feb 28, 2022 | 9.29 Mn |
| Nov 30, 2021 | 6.00 Mn |
| Aug 31, 2021 | 7.05 Mn |